Bellerophon Announces FDA Acceptance of Change to Ongoing Phase III REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

Bellerophon Therapeutics, Inc. announced that the FDA has accepted the company’s proposal to reduce the study size for its ongoing registrational REBUILD Phase III trial of INOpulse® for the treatment of fibrotic interstitial lung disease.